hvd medical GmbH
- Legal form
- GmbH
- Seat
- Saarlouis, Germany
Based on the notices and sources Inteliwert covers; not a complete record. Last checked 5 August 2026.
Identifiers
Not found in the indexed notices.
Track record in public tenders
Awards in the covered notices over the last 36 months, per CPV division.
| CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award |
|---|---|---|---|---|---|---|
| 33 Medical equipments, pharmaceuticals and personal care products | 1 | €1 | 1 | 0 | 5 August 2026 | 5 August 2026 |
Awards
- Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zwischen der IKK classic und der hcd medical GmbH zu VabysmoBuyer: IKK classic · Award value: €1 excl. VAT · Awarded: 5 August 2026 · CPV 33600000
Certifications and prequalification
No certification or prequalification found in the covered sources.
A certification missing here is unknown, not absent.
Website and LinkedIn
Not found in the indexed notices.
Open tenders that might fit
Possible match based on public information
Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances.
-
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Naloxegol, ATC A06AH03 für die Zeit 01.08.2026 - 31.07.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 12 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 11 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 12 Nov 2026
Last checked 11 Nov 2026, 19:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon alfa-2a, ATC L03AB11 für die Zeit 01.08.2026 - 31.07.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 12 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 11 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 12 Nov 2026
Last checked 11 Nov 2026, 19:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Budesonid (FAM Kinpeygo und austauschbare Arzneimittel), ATC A07EA06 für die Zeit 01.08.2026 - 31.07.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 12 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 11 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 12 Nov 2026
Last checked 11 Nov 2026, 19:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Omalizumab, ATC L04AG08 für die Zeit 01.08.2026 - 31.07.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 12 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 11 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 12 Nov 2026
Last checked 11 Nov 2026, 19:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tocilizumab (ausschließlich Darreichungsform PEN und FER), ATC L04AC07 für die Zeit 01.08.2026 - 31.07.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 12 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 11 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 12 Nov 2026
Last checked 11 Nov 2026, 19:31 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ranibizumab, ATC S01LA04 für die Zeit 01.09.2026 - 31.08.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 10 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 10 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 10:30 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Abatacept, ATC L04AA24 für die Zeit 01.09.2026 - 31.08.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 10 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 10 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 10:30 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brolucizumab, ATC S01LA06 für die Zeit 01.09.2026 - 31.08.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 10 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 10 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 10:30 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Umeclidinium + Vilanterol, ATC R03AL03 für die Zeit 01.09.2026 - 31.08.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 10 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 10 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 10:30 (UTC+01:00)Official notice -
OpenTenderSME (from the award notice)New to public tenders
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Triptorelin, ATC L02AE04 für die Zeit 01.09.2026 - 31.08.2028
Reasons
- Won a contract in CPV group 336 (2026-08-05) Evidence · checked 10 Nov 2026
- The contract value is close to the values of its past awards Evidence · checked 10 Nov 2026
- 1 award in this field in 36 months, from 1 buyer Evidence · checked 10 Nov 2026
Last checked 10 Nov 2026, 10:30 (UTC+01:00)Official notice
Is this your company?
Send corrections, or ask us to remove the profile, to hello@inteliwert.com. You can also ask that the company never be tagged on LinkedIn.
About this profile
Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances.
Based on the notices and sources Inteliwert covers; not a complete record.
Last checked 5 August 2026.